An emerging role of degrading proteinases in hypertension and the metabolic syndrome: Autodigestion and receptor cleavage

Current Hypertension Reports

Volumn 14, Issue 1, 2012, Pages 88-96

  Schmid Schönbein, Geert W ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

ADAM; Angiotensin; Angiotensin converting enzyme; Arteriole; Artery; Beta adrenergic receptor; Capillary rarefaction; Essential hypertension; Extracellular matrix protein; Hypertension; Hypertrophy; Immune suppression; Insulin receptor; Insulin resistance; Matrix metalloproteinase; Metabolic syndrome; Microcirculation; MMP; NF kappaB; Pathogenesis; Proteinase inhibitor; Spontaneously hypertensive rat; Vascular endothelial growth factor receptor

Indexed keywords

ADAM 12 PROTEIN; ADAM PROTEIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME PRECURSOR; GELATINASE A; GELATINASE B; MATRILYSIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; PEPTIDE; PROTEINASE; RECEPTOR; STROMELYSIN; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR RISK; CELL DAMAGE; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME SUBSTRATE; EXTRACELLULAR MATRIX; HEART HYPERTROPHY; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; MATRIX METALLOPROTEINASE BLOOD LEVEL; METABOLIC SYNDROME X; NONHUMAN; PATHOPHYSIOLOGY; PREHYPERTENSION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; VASOCONSTRICTION;

COMORBIDITY; EXTRACELLULAR MATRIX PROTEINS; HUMANS; HYPERTENSION; HYPERTROPHY; IMMUNE TOLERANCE; MATRIX METALLOPROTEINASES; METABOLIC SYNDROME X; MICROCIRCULATION; MODELS, BIOLOGICAL; RECEPTORS, CELL SURFACE; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; VASOCONSTRICTION;

EID: 84857635793     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-011-0240-9     Document Type: Article

References (99)

1. GM Reaven 1988 Banting lecture 1988. Role of insulin resistance in human disease Diabetes 37 12 1595 1607 3056758 10.2337/diabetes.37.12.1595 1:STN:280:DyaL1M%2Flt12msQ%3D%3D
2. T Klein R Bischoff 2010 Physiology and pathophysiology of matrix metalloproteases Amino Acids 41 2 271 290 20640864 10.1007/s00726-010-0689-x
3. ZS Galis JJ Khatri 2002 Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly Circ Res 90 3 251 262 11861412 1:CAS:528:DC%2BD38Xhs1Wrsb4%3D
4. JA Rodriguez J Orbe S Martinez de Lizarrondo, et al. 2008 Metalloproteinases and atherothrombosis: MMP-10 mediates vascular remodeling promoted by inflammatory stimuli Front Biosci 13 2916 2921 17981764 10.2741/2896 1:CAS:528:DC%2BD1cXhs1Cnsbo%3D
5. P Ronco B Lelongt R Piedagnel C Chatziantoniou 2007 Matrix metalloproteinases in kidney disease progression and repair: a case of flipping the coin Semin Nephrol 27 3 352 362 17533011 10.1016/j.semnephrol.2007.02.006 1:CAS:528:DC%2BD2sXot1ejurk%3D
6. KM Thrailkill 2009 Clay Bunn R, Fowlkes JL: Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy Endocrine 35 1 1 10 18972226 10.1007/s12020-008-9114-6 1:CAS:528:DC%2BD1MXhvVyltrs%3D
7. A Rosell EH Lo 2008 Multiphasic roles for matrix metalloproteinases after stroke Curr Opin Pharmacol 8 1 82 89 18226583 10.1016/j.coph.2007.12.001 1:CAS:528:DC%2BD1cXhsVOgu7s%3D
8. Moore L, Fan D, Basu R, et al.: Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Fail Rev 2011 Jun 30 (Epub ahead of print).
9. MM Turu J Krupinski E Catena, et al. 2006 Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound Atherosclerosis 187 1 161 169 16259988 10.1016/j.atherosclerosis.2005.08.039 1:CAS:528:DC%2BD28XltlentLc%3D
10. Y Iwanaga T Aoyama Y Kihara, et al. 2002 Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats J Am Coll Cardiol 39 8 1384 1391 11955860 10.1016/S0735-1097(02)01756-4 1:CAS:528:DC%2BD38XjsFait7w%3D
11. BH Shah KJ Catt 2004 Matrix metalloproteinase-dependent EGF receptor activation in hypertension and left ventricular hypertrophy Trends Endocrinol Metab 15 6 241 243 15358274 10.1016/j.tem.2004.06.011 1:CAS:528: DC%2BD2cXmsVGju7o%3D
12. MH Tayebjee RJ MacFadyen GY Lip 2003 Extracellular matrix biology: a new frontier in linking the pathology and therapy of hypertension? J Hypertens 21 12 2211 2218 14654734 10.1097/00004872-200312000-00002 1:CAS:528: DC%2BD3sXpsVGhsr0%3D
13. FZ Ammarguellat PO Gannon F Amiri EL Schiffrin 2002 Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors Hypertension 39 2 Pt 2 679 684 11882630 10.1161/hy0202.103481 1:CAS:528:DC%2BD38Xhs1Wqt7g%3D
14. FG Spinale 2002 Matrix metalloproteinases: regulation and dysregulation in the failing heart Circ Res 90 5 520 530 11909815 10.1161/01.RES.0000013290. 12884.A3 1:CAS:528:DC%2BD38XisFSks74%3D
15. JR Barbour FG Spinale JS Ikonomidis 2007 Proteinase systems and thoracic aortic aneurysm progression J Surg Res 139 2 292 307 17292415 10.1016/j.jss.2006.09.020 1:CAS:528:DC%2BD2sXktF2ku78%3D
16. H Kaneko T Anzai K Horiuchi, et al. 2011 Tumor necrosis factor-alpha converting enzyme is a key mediator of abdominal aortic aneurysm development Atherosclerosis 218 2 470 478 21722904 10.1016/j.atherosclerosis.2011.06.008 1:CAS:528:DC%2BC3MXht1GrsbvM
17. HD Intengan EL Schiffrin 2001 Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis Hypertension 38 3 Pt 2 581 587 11566935 10.1161/hy09t1.096249 1:CAS:528:DC%2BD3MXntFSrtrc%3D
18. JD Raffetto RA Khalil 2008 Matrix metalloproteinases in venous tissue remodeling and varicose vein formation Curr Vasc Pharmacol 6 3 158 172 18673156 10.2174/157016108784911957 1:CAS:528:DC%2BD1cXnsVOqs7s%3D
19. S Lehoux CA Lemarie B Esposito, et al. 2004 Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling Circulation 109 8 1041 1047 14967734 10.1161/01.CIR.0000115521.95662.7A 1:CAS:528: DC%2BD2cXhsFeisb8%3D
20. JP Spiers EJ Kelso WF Siah, et al. 2005 Alterations in vascular matrix metalloproteinase due to ageing and chronic hypertension: effects of endothelin receptor blockade J Hypertens 23 9 1717 1724 16093917 10.1097/01.hjh.0000176787. 04753.ee 1:CAS:528:DC%2BD2MXnt1yku78%3D
21. VS Mujumdar LM Smiley SC Tyagi 2001 Activation of matrix metalloproteinase dilates and decreases cardiac tensile strength Int J Cardiol 79 2-3 277 286 11461752 10.1016/S0167-5273(01)00449-1 1:STN:280: DC%2BD3Mvht1WktA%3D%3D
22. A Ergul V Portik-Dobos AD Giulumian, et al. 2003 Stress upregulates arterial matrix metalloproteinase expression and activity via endothelin A receptor activation Am J Physiol Heart Circ Physiol 285 5 H2225 2232 12842810 1:CAS:528:DC%2BD3sXpt1Oksbs%3D
23. C Bouvet LA Gilbert D Girardot, et al. 2005 Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition Hypertension 45 3 432 437 15655118 10.1161/01.HYP. 0000154680.44184.01 1:CAS:528:DC%2BD2MXhtlOisLs%3D
24. TM Seccia E Bettini V Vulpis, et al. 1999 Extracellular matrix gene expression in the left ventricular tissue of spontaneously hypertensive rats Blood Press 8 1 57 64 10412884 10.1080/080370599438400 1:CAS:528: DyaK1MXkt12qt74%3D
25. T Shinzato Y Ohya M Nakamoto, et al. 2007 Beneficial effects of pioglitazone on left ventricular hypertrophy in genetically hypertensive rats Hypertens Res 30 9 863 873 18037780 10.1291/hypres.30.863 1:CAS:528: DC%2BD2sXhsVyjtrvO
26. WE Rodriguez N Tyagi AY Deng, et al. 2008 Congenic expression of tissue inhibitor of metalloproteinase in Dahl-salt sensitive hypertensive rats is associated with reduced LV hypertrophy Arch Physiol Biochem 114 5 340 348 19003589 10.1080/13813450802535978 1:CAS:528:DC%2BD1MXhtVKmsbc%3D
27. TL Haas JL Doyle MR Distasi, et al. 2007 Involvement of MMPs in the outward remodeling of collateral mesenteric arteries Am J Physiol Heart Circ Physiol 293 4 H2429 2437 17644578 10.1152/ajpheart.00100.2007 1:CAS:528:DC%2BD2sXht1WlurfE
28. O Dumont L Loufrani D Henrion 2007 Key role of the NO-pathway and matrix metalloprotease-9 in high blood flow-induced remodeling of rat resistance arteries Arterioscler Thromb Vasc Biol 27 2 317 324 17158349 10.1161/01.ATV.0000254684.80662.44 1:CAS:528:DC%2BD2sXjvFKhtg%3D%3D
29. KN Cowan PL Jones M Rabinovitch 2000 Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease J Clin Invest 105 1 21 34 10619858 10.1172/JCI6539 1:CAS:528:DC%2BD3cXislSkuw%3D%3D
30. JD Raffetto RA Khalil 2008 Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease Biochem Pharmacol 75 2 346 359 17678629 10.1016/j.bcp.2007.07.004 1:CAS:528:DC%2BD1cXhsVynsg%3D%3D
31. X Wang FL Chow T Oka, et al. 2009 Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy Circulation 119 18 2480 2489 19398663 10.1161/CIRCULATIONAHA.108.835488 1:CAS:528:DC%2BD1MXls1Gks78%3D This article demonstrates that hypertension and hypertrophy depend on transcriptional and posttranscriptional mechanisms involving MMP-7 and transcriptional connection with ADAM-12
32. N Prenzel E Zwick H Daub, et al. 1999 EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF Nature 402 6764 884 888 10622253 1:CAS:528:DC%2BD3cXitFSltQ%3D%3D
33. L Hao M Du A Lopez-Campistrous C Fernandez-Patron 2004 Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway Circ Res 94 1 68 76 14656925 10.1161/01.RES.0000109413.57726.91 1:CAS:528:DC%2BD2cXhtFWi
34. X Wang T Oka FL Chow, et al. 2009 Tumor necrosis factor-alpha-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis Hypertension 54 3 575 582 19581512 10.1161/HYPERTENSIONAHA.108.127670 1:CAS:528:DC%2BD1MXpsleks7k%3D This article demonstrates that agonist-induced cardiac hypertrophy and fibrosis processes are signaled through TNF-α-converting enzyme by transcriptional regulation of ADAM-12 and MMP-2
35. J Odenbach X Wang S Cooper, et al. 2010 MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE Hypertension 57 1 123 130 21079048 10.1161/HYPERTENSIONAHA.110.159525 This article demonstrates that in the angiotensin II-induced hypertension model, MMP-7 and TNF-α-converting enzyme mediate fibrosis and hypertrophy and induce MMP-2 upregulation. The MMP-2 induces hypertension without hypertrophy
36. GS Butler RA Dean CJ Morrison CM Overall 2010 Identification of cellular MMP substrates using quantitative proteomics: isotope-coded affinity tags (ICAT) and isobaric tags for relative and absolute quantification (iTRAQ) Methods Mol Biol 622 451 470 20135298 10.1007/978-1-60327-299-5-26 1:CAS:528: DC%2BC3cXoslyqs7c%3D This paper describes a quantitative proteomics and mass spectrometry technique to identify protease substrates in a cell
37. CM Overall GA McQuibban I Clark-Lewis 2002 Discovery of chemokine substrates for matrix metalloproteinases by exosite scanning: a new tool for degradomics Biol Chem 383 7-8 1059 1066 12437088 10.1515/BC.2002.114 1:CAS:528:DC%2BD38Xptl2itL4%3D
38. A Prudova U auf dem Keller GS Butler CM Overall 2010 Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQ-TAILS quantitative proteomics Mol Cell Proteomics 9 5 894 911 20305284 10.1074/mcp.M000050-MCP201 1:CAS:528:DC%2BC3cXpslyrsLY%3D This paper reports the development of a method for proteome-wide detection of protease-generated neo-N-termini
39. A Martinez HR Oh EJ Unsworth, et al. 2004 Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator Biochem J 383 Pt. 3 413 418 15307819 1:CAS:528:DC%2BD2cXovVOhtr8%3D
40. ED Lekgabe H Kiriazis C Zhao, et al. 2005 Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats Hypertension 46 2 412 418 15967869 10.1161/01.HYP.0000171930.00697.2f 1:CAS:528:DC%2BD2MXmtlSjurg%3D
41. RC Tostes RM Touyz G He, et al. 2002 Endothelin A receptor blockade decreases expression of growth factors and collagen and improves matrix metalloproteinase-2 activity in kidneys from stroke-prone spontaneously hypertensive rats J Cardiovasc Pharmacol 39 6 892 900 12021584 10.1097/00005344-200206000-00015 1:CAS:528:DC%2BD38XktFWhurk%3D
42. H Xue YL Zhang GS Liu H Wang 2005 A new ATP-sensitive potassium channel opener protects the kidney from hypertensive damage in spontaneously hypertensive rats J Pharmacol Exp Ther 315 2 501 509 16051697 10.1124/jpet.105.089722 1:CAS:528:DC%2BD2MXhtFyhsbbJ
43. TM Camp LM Smiley MR Hayden SC Tyagi 2003 Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats J Hypertens 21 9 1719 1727 12923405 10.1097/00004872-200309000-00022 1:CAS:528:DC%2BD3sXmtl2ksLc%3D
44. ED Tran FA DeLano GW Schmid-Schönbein 2010 Enhanced matrix metalloproteinase activity in the spontaneously hypertensive rat: VEGFR-2 cleavage, endothelial apoptosis, and capillary rarefaction J Vasc Res 47 5 423 431 20145415 10.1159/000281582 1:CAS:528:DC%2BC3cXhtVersrbE This paper demonstrates that extracellular-domain VEGFR-2 receptor cleavage by MMPs is a basis for endothelial apoptosis and capillary rarefaction in the SHR
45. FA DeLano GW Schmid-Schönbein 2008 Proteinase activity and receptor cleavage: mechanism for insulin resistance in the spontaneously hypertensive rat Hypertension 52 2 415 423 18606910 10.1161/HYPERTENSIONAHA.107.104356 1:CAS:528:DC%2BD1cXosF2js78%3D
46. E Tran M Yang A Chen, et al. 2011 Matrix metalloproteinase activity causes VEGFR-2 cleavage and microvascular rarefaction in rat mesentery Microcirculation 18 1 10 10.1111/j.1549-8719.2011.00082.x
47. SF Rodrigues ED Tran ZB Fortes GW Schmid-Schönbein 2010 Matrix metalloproteinases cleave the beta2-adrenergic receptor in spontaneously hypertensive rats Am J Physiol Heart Circ Physiol 299 1 H25 H35 20382857 10.1152/ajpheart.00620.2009 1:CAS:528:DC%2BC3cXpsVOrsrk%3D This article demonstrates that extracellular domain vasodilatory receptor cleavage by MMPs is a basis for arteriolar constriction and elevated blood pressure in the SHR
48. GW Schmid-Schönbein BW Zweifach FA DeLano P Chen 1987 Microvascular tone in a skeletal muscle of spontaneously hypertensive rats Hypertension 9 164 171 3818013
49. MA Potenza FL Marasciulo DM Chieppa, et al. 2005 Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production Am J Physiol Heart Circ Physiol 289 2 H813 822 15792994 10.1152/ajpheart.00092.2005 1:CAS:528:DC%2BD2MXotFejsrg%3D
50. FA Delano H Zhang EE Tran, et al. 2010 A new hypothesis for insulin resistance in hypertension due to receptor cleavage Expert Rev Endocrinol Metab 5 1 149 158 21132054 1:CAS:528:DC%2BD1MXhsFyiu7%2FE
51. HG Bohlen 1989 The microcirculation in hypertension J Hypertens Suppl 7 4 S117 124 2681589 1:STN:280:DyaK3c%2FjvFKmsQ%3D%3D
52. GL Penna F Garbero Rde MF Neves, et al. 2008 Treatment of essential hypertension does not normalize capillary rarefaction Clinics (Sao Paulo) 63 5 613 618 10.1590/S1807-59322008000500008
53. JP Noon BR Walker DJ Webb, et al. 1997 Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure J Clin Invest 99 8 1873 1879 9109431 10.1172/JCI119354 1:CAS:528:DyaK2sXisF2qt7s%3D
54. ED Tran GW Schmid-Schönbein 2007 An in-vivo analysis of capillary stasis and endothelial apoptosis in a model of hypertension Microcirculation 14 8 793 804 17924279 10.1080/10739680701419992 1:CAS:528:DC%2BD2sXht12jtrnL
55. HH Lim FA DeLano GW Schmid-Schönbein 2001 Life and death cell labeling in the microcirculation of the spontaneously hypertensive rat J Vasc Res 38 3 228 236 11399895 10.1159/000051051 1:STN:280:DC%2BD3Mzjt1Sqtg%3D%3D
56. WL Murfee GW Schmid-Schönbein 2008 Chapter 12. Structure of microvascular networks in genetic hypertension Methods Enzymol 444 271 284 19007669 10.1016/S0076-6879(08)02812-7 1:CAS:528:DC%2BD1cXhsVartrzK
57. H Wang B Olszewski W Rosebury, et al. 2004 Impaired angiogenesis in SHR is associated with decreased KDR and MT1-MMP expression Biochem Biophys Res Commun 315 2 363 368 14766216 10.1016/j.bbrc.2004.01.059 1:CAS:528: DC%2BD2cXps1Ogtw%3D%3D
58. AY Chen FA DeLano SR Valdez, et al. 2010 Receptor cleavage reduces the fluid shear response in neutrophils of the spontaneously hypertensive rat Am J Physiol Cell Physiol 299 6 C1441 C1449 20861466 10.1152/ajpcell.00157.2010 1:CAS:528:DC%2BC3cXhs1aisbnM This is a demonstration of extracellular domain chemotactic receptor cleavage in the SHR by MMPs as a contribution to attenuated chemotactic and fluid shear stress response in leukocytes
59. A Makino ER Prossnitz M Bünemann, et al. 2006 G Protein-coupled receptors serve as mechanosensors for fluid shear stress in neutrophils Am J Physiol Cell Physiol 290 C1633 C1639 16436471 10.1152/ajpcell.00576.2005 1:CAS:528:DC%2BD28XlvVejtb8%3D
60. S Fukuda T Yasu N Kobayashi, et al. 2004 Contribution of fluid shear response in leukocytes to hemodynamic resistance in the spontaneously hypertensive rat Circ Res 95 1 100 108 15166092 10.1161/01.RES.0000133677.77465. 38 1:CAS:528:DC%2BD2cXlt1Cru78%3D
61. GW Schmid-Schönbein D Seiffge FA DeLano, et al. 1991 Leukocyte counts and activation in spontaneously hypertensive and normotensive rats Hypertension 17 323 330 1999363
62. S Tong HJ Neboori ED Tran GW Schmid-Schönbein 2011 Constitutive expression and enzymatic cleavage of ICAM-1 in the spontaneously hypertensive rat J Vasc Res 48 386 396 21464573 10.1159/000323474 1:CAS:528: DC%2BC3MXhtVWrsLvK
63. Pot C, Chen AY, Ha JN, Schmid-Schönbein GW: Proteolytic cleavage of the red blood cell glycocalyx in a genetic form of hypertension. Cell Mol Bioeng 2011. doi: 10.1007/s12195-011-0180-0.
64. Y Yang EY Estrada JF Thompson, et al. 2007 Matrix metalloproteinase- mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat J Cereb Blood Flow Metab 27 4 697 709 16850029 1:CAS:528:DC%2BD2sXkvFyntLo%3D
65. Valdez SR. Serotonin 5HT-1A Receptor Density in the Brain of Spontaneously Hypertensive Rats. M.S. Thesis. La Jolla, Univ. Calif. San Diego; 2010.
66. TB Kuo FZ Shaw CJ Lai, et al. 2004 Changes in sleep patterns in spontaneously hypertensive rats Sleep 27 3 406 412 15164892
67. JT Peterson 2004 Matrix metalloproteinase inhibitor development and the remodeling of drug discovery Heart Fail Rev 9 1 63 79 14739769 10.1023/B:HREV.0000011395.11179.af 1:CAS:528:DC%2BD2cXisVegug%3D%3D
68. Castro MM, Tanus-Santos JE, Gerlach RF: Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension. Pharmacol Res 2011 Apr 9 (Epub ahead of print).
69. IM Clark TE Swingler CL Sampieri DR Edwards 2008 The regulation of matrix metalloproteinases and their inhibitors Int J Biochem Cell Biol 40 6-7 1362 1378 18258475 10.1016/j.biocel.2007.12.006 1:CAS:528:DC%2BD1cXlslGlu7o%3D
70. KI Wu GW Schmid-Schönbein 2011 Nuclear factor kappa B and matrix metalloproteinase induced receptor cleavage in the spontaneously hypertensive rat Hypertension 57 2 261 268 21220710 10.1161/HYPERTENSIONAHA.110.158709 1:CAS:528:DC%2BC3MXnvVWmsQ%3D%3D This is a demonstration of NFκB-dependent MMP overexpression, vasodilatory receptor cleavage, and elevated blood pressure in the SHR
71. M Liebetrau D Burggraf N Wunderlich, et al. 2005 ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke-prone rats Neurosci Lett 376 3 205 209 15721222 10.1016/j.neulet.2004.11.061 1:CAS:528:DC%2BD2MXhtlOltbw%3D
72. D Yamamoto S Takai 2009 Pharmacological implications of MMP-9 inhibition by ACE inhibitors Curr Med Chem 16 11 1349 1354 19355890 10.2174/ 092986709787846514 1:CAS:528:DC%2BD1MXltVeqsbg%3D
73. M Pahor BM Psaty MH Alderman, et al. 2000 Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes Diabetes Care 23 7 888 892 10895836 10.2337/diacare.23.7.888 1:CAS:528:DC%2BD3cXnvV2is74%3D
74. EL Gillespie CM White M Kardas, et al. 2005 The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes Diabetes Care 28 9 2261 2266 16123505 10.2337/diacare.28.9.2261 1:CAS:528:DC%2BD2MXhtVGntr3J
75. ME Ryan NS Ramamurthy T Sorsa LM Golub 1999 MMP-mediated events in diabetes Ann N Y Acad Sci 878 311 334 10415738 10.1111/j.1749-6632.1999.tb07692. x 1:CAS:528:DyaK1MXkslems7o%3D
76. M Saglam O Karakaya AM Esen, et al. 2006 Contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy and diastolic dysfunction in hypertensive subjects Tohoku J Exp Med 208 2 117 122 16434834 10.1620/tjem.208.117 1:CAS:528:DC%2BD28XhsFeisb4%3D
77. C Fernandez-Patron Y Zhang MW Radomski, et al. 1999 Rapid release of matrix metalloproteinase (MMP)-2 by thrombin in the rat aorta: modulation by protein tyrosine kinase/phosphatase Thromb Haemost 82 4 1353 1357 10544927 1:CAS:528:DyaK1MXmsFansbs%3D
78. HS Rosario SW Waldo SA Becker GW Schmid-Schönbein 2004 Pancreatic trypsin increases matrix metalloproteinase-9 accumulation and activation during acute intestinal ischemia-reperfusion in the rat Am J Pathol 164 5 1707 1716 15111317 10.1016/S0002-9440(10)63729-7 1:CAS:528:DC%2BD2cXns1Gqu7w%3D
79. K Asanuma R Magid C Johnson, et al. 2003 Uniaxial strain upregulates matrix-degrading enzymes produced by human vascular smooth muscle cells Am J Physiol Heart Circ Physiol 284 5 H1778 1784 12543633 1:CAS:528: DC%2BD3sXjvFGrtb0%3D
80. K Grote I Flach M Luchtefeld, et al. 2003 Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species Circ Res 92 11 e80 86 12750313 10.1161/01.RES.0000077044.60138.7C 1:CAS:528:DC%2BD3sXkt12qtb4%3D
81. PM Cummins N von Offenberg Sweeney MT Killeen, et al. 2007 Cyclic strain-mediated matrix metalloproteinase regulation within the vascular endothelium: a force to be reckoned with Am J Physiol Heart Circ Physiol 292 1 H28 H42 16951049 10.1152/ajpheart.00304.2006 1:CAS:528:DC%2BD2sXisFGjtb0%3D
82. EI Deryugina B Ratnikov E Monosov, et al. 2001 MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells Exp Cell Res 263 2 209 223 11161720 10.1006/excr.2000. 5118 1:CAS:528:DC%2BD3MXnsFSgtA%3D%3D
83. D Guo Z Kassiri R Basu, et al. 2010 Loss of PI3Kgamma enhances cAMP-dependent MMP remodeling of the myocardial N-cadherin adhesion complexes and extracellular matrix in response to early biomechanical stress Circ Res 107 10 1275 1289 20847309 10.1161/CIRCRESAHA.110.229054 1:CAS:528: DC%2BC3cXhsVWht7%2FI
84. CJ Malemud 2006 Matrix metalloproteinases (MMPs) in health and disease: an overview Front Biosci 11 1696 1701 16368548 10.2741/1915 1:CAS:528: DC%2BD28XislSnsLw%3D
85. SJ Weiss G Peppin X Ortiz, et al. 1985 Oxidative autoactivation of latent collagenase by human neutrophils Science 227 4688 747 749 2982211 10.1126/science.2982211 1:CAS:528:DyaL2MXptl2msw%3D%3D
86. V Fontana PS Silva VA Belo, et al. 2011 Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target Basic Clin Pharmacol Toxicol 109 2 130 137 21401887 10.1111/j.1742-7843.2011.00698.x 1:CAS:528:DC%2BC3MXpvVSjsr4%3D
87. RB Lefkowitz GW Schmid-Schönbein MJ Heller 2010 Whole blood assay for elastase, chymotrypsin, matrix metalloproteinase-2, and matrix metalloproteinase-9 activity Anal Chem 82 19 8251 8258 20828137 10.1021/ac101462c 1:CAS:528:DC%2BC3cXhtFartr3K
88. RS Friese F Rao S Khandrika, et al. 2009 Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease Clin Exp Hypertens 31 7 521 533 19886850 10.3109/10641960802668730 1:CAS:528:DC%2BD1MXhsVCqtbrK
89. DP Papadopoulos TK Makris PG Krespi, et al. 2005 Changes in metalloproteinases in healthy normotensive patients with high-normal blood pressure Eur Cytokine Netw 16 3 211 214 16266862 1:CAS:528:DC%2BD2MXhtlaltrbP
90. G Derosa A D'Angelo L Ciccarelli, et al. 2006 Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension Endothelium 13 3 227 231 16840178 10.1080/10623320600780942 1:CAS:528: DC%2BD28XoslCms7s%3D
91. J Tan Q Hua X Xing, et al. 2007 Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension Hypertens Res 30 10 959 963 18049028 10.1291/hypres.30.959 1:CAS:528:DC%2BD1cXht12lsL0%3D
92. J Ishikawa K Kario Y Matsui, et al. 2005 Collagen metabolism in extracellular matrix may be involved in arterial stiffness in older hypertensive patients with left ventricular hypertrophy Hypertens Res 28 12 995 1001 16671339 10.1291/hypres.28.995 1:CAS:528:DC%2BD28XivVWhsbY%3D
93. Yasmin CM McEniery S Wallace, et al. 2005 Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness Arterioscler Thromb Vasc Biol 25 2 372 15556929 10.1161/01.ATV.0000151373.33830.41 1:CAS:528:DC%2BD2MXmtFCmsQ%3D%3D
94. O Hirono K Fatema J Nitobe, et al. 2002 Long-term effects of benidipine hydrochloride on severe left ventricular hypertrophy and collagen metabolism in patients with essential hypertension J Cardiol 39 4 195 204 11977767
95. SH Ahmed LL Clark WR Pennington, et al. 2006 Matrix metalloproteinases/ tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease Circulation 113 17 2089 2096 16636176 10.1161/CIRCULATIONAHA.105.573865 1:CAS:528:DC%2BD28XjslKiur8%3D
96. A Zervoudaki E Economou C Pitsavos, et al. 2004 The effect of Ca2+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and -9 in essential hypertension Am J Hypertens 17 3 273 276 15001203 10.1016/j.amjhyper.2003.11.007 1:CAS:528:DC%2BD2cXhs12ns7g%3D
97. FL Li-Saw-Hee E Edmunds AD Blann, et al. 2000 Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy Int J Cardiol 75 1 43 47 11054505 10.1016/S0167-5273(00)00274-6 1:STN:280: DC%2BD3M%2Fks1Smsw%3D%3D
98. C Laviades N Varo J Fernandez, et al. 1998 Abnormalities of the extracellular degradation of collagen type I in essential hypertension Circulation 98 6 535 540 9714110 1:CAS:528:DyaK1cXlsF2ltbg%3D
99. R Lacchini AL Jacob-Ferreira MR Luizon, et al. 2010 Matrix metalloproteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients Clin Chim Acta 411 23-24 1940 1944 20707992 10.1016/j.cca.2010.08.008 1:CAS:528:DC%2BC3cXht1OgsLnP